CLINICAL TRIALS PROFILE FOR MOVANTIK
✉ Email this page to a colleague
All Clinical Trials for MOVANTIK
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02705378 ↗ | The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit | Withdrawn | AstraZeneca | Phase 3 | 2017-05-01 | Naloxegol has recently been approved by the US Food and Drug Administration to treat opioid induced constipation in non-cancer chronic pain patients. Its effectiveness in acute care patients, however, is not known. Therefore, the researchers' goal is to investigate whether naloxegol is superior to osmotic laxatives for refractory constipation in ICU patients already receiving prophylactic stool softeners and simulant laxatives through a double-blind, randomized control trial. |
| NCT02705378 ↗ | The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit | Withdrawn | Massachusetts General Hospital | Phase 3 | 2017-05-01 | Naloxegol has recently been approved by the US Food and Drug Administration to treat opioid induced constipation in non-cancer chronic pain patients. Its effectiveness in acute care patients, however, is not known. Therefore, the researchers' goal is to investigate whether naloxegol is superior to osmotic laxatives for refractory constipation in ICU patients already receiving prophylactic stool softeners and simulant laxatives through a double-blind, randomized control trial. |
| NCT02737059 ↗ | Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects | Completed | AstraZeneca | Phase 1 | 2016-07-01 | This research study was being done to study the effect of codeine and Naloxegol for 3 days compared to placebo on the movement of food through the colon of healthy individuals. Codeine is a commonly used pain-relieving drug that often causes constipation as an unwanted side effect. Naloxegol is a medication recently approved by the FDA for treatment of constipation induced by Codeine. The hypothesis for this study was that Naloxegol reduces the retardation of small bowel and colonic transit induced by codeine in healthy participants. |
| NCT02737059 ↗ | Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects | Completed | Michael Camilleri | Phase 1 | 2016-07-01 | This research study was being done to study the effect of codeine and Naloxegol for 3 days compared to placebo on the movement of food through the colon of healthy individuals. Codeine is a commonly used pain-relieving drug that often causes constipation as an unwanted side effect. Naloxegol is a medication recently approved by the FDA for treatment of constipation induced by Codeine. The hypothesis for this study was that Naloxegol reduces the retardation of small bowel and colonic transit induced by codeine in healthy participants. |
| NCT02745353 ↗ | Naloxegol in Cancer Opioid-Induced Constipation | Terminated | AstraZeneca | Phase 2 | 2016-05-01 | The purpose of this study is to compare the effect of naloxegol versus the patient's usual care in treating opioid-induced constipation, as well as the effect on the patient's quality of life and how much pain is experienced. Also, the purpose of this study is to compare whether treatment with naloxegol versus usual care has any impact on the number of hospital or clinic visits or telephone calls to the patient's physician that are related to constipation, and to determine the patient's preference for continuing to receive naloxegol as treatment for opioid-induced constipation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MOVANTIK
Condition Name
Clinical Trial Locations for MOVANTIK
Trials by Country
Clinical Trial Progress for MOVANTIK
Clinical Trial Phase
Clinical Trial Sponsors for MOVANTIK
Sponsor Name
